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Abstract
In recent years, the number of mathematical modelling studies has increased
steeply. Many of the questions addressed in these studies are relevant to the
development of World Health Organization (WHO) guidelines, but modelling
studies are rarely formally included as part of the body of evidence. An expert
consultation hosted by WHO, a survey of modellers and users of modelling
studies, and literature reviews informed the development of recommendations
on when and how to incorporate the results of modelling studies into WHO
guidelines. In this article, we argue that modelling studies should routinely be
considered in the process of developing WHO guidelines, but particularly in the
evaluation of public health programmes, long-term effectiveness or
comparative effectiveness.  There should be a systematic and transparent
approach to identifying relevant published models, and to commissioning new
models.  We believe that the inclusion of evidence from modelling studies into
the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) process is possible and desirable, with relatively few adaptations.  No
single “one-size-fits-all” approach is appropriate to assess the quality of
modelling studies. The concept of the ‘credibility’ of the model, which takes the
conceptualization of the problem, model structure, input data, different
dimensions of uncertainty, as well as transparency and validation into account,
is more appropriate than ‘risk of bias’.
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Introduction
Mathematical models have a long history in public health1. In 1760, 
Daniel Bernoulli developed a model of smallpox transmission and 
control. William Hamer published a measles transmission model 
in 1906 and Ronald Ross a model of malaria transmission in 1908. 
In recent years, the number of publications related to mathematical 
modelling has increased steeply. Today, mathematical modelling 
studies are not restricted to infectious diseases but address a wide 
range of questions.
The World Health Organization (WHO) provides recommendations 
on many public health, health system and clinical topics. WHO 
guidelines are developed using processes and methods that ensure 
the publication of high-quality recommendations, as outlined in the 
WHO Handbook for Guideline Development2. WHO uses the Grad-
ing of Recommendations Assessment, Development and Evaluation 
(GRADE) approach to rate the certainty of a body of evidence and 
to produce information that is used by guideline panels to formulate 
recommendations, based on the balance of benefits and harms and 
other considerations3.
Many of the questions addressed in mathematical modelling 
studies are relevant to the development of guidelines. Increas-
ingly, WHO and other guideline developers need to decide whether 
and how the results of mathematical modelling studies should be 
included in the evidence base used to develop recommendations. 
We reviewed the 185 WHO guidelines that were approved by 
the Guidelines Review Committee from 2007 to 2015: 42 (23%) 
referred to mathematical modelling studies. However, these stud-
ies were rarely formally assessed as part of the body of evidence, 
and quality criteria for modelling studies were often lacking. 
A major barrier to the incorporation of evidence from mathemati-
cal modelling studies into guidelines is the perceived complexity 
of the methods used to construct and analyse these studies. At 
present, there are no widely agreed methods for, or approaches 
to, the evaluation of the results of mathematical modelling 
studies, and to their integration with primary data to inform 
guidelines and recommendations. In April 2016 WHO organized 
a workshop in Geneva, Switzerland to discuss when and how to 
incorporate the results of modelling studies into WHO guidelines 
(see Acknowledgements for names of participants; see the Meeting 
Report). Specifically, the following three questions were discussed 
at the workshop:
(1) When is it appropriate to consider modelling studies as part of 
the evidence that supports a guideline?
(2) How should the quality and risk of bias in mathematical model-
ling studies be assessed?
(3) How can the GRADE approach be adapted to assess the cer-
tainty of a body of evidence that includes the results of modelling 
and to formulate recommendations?
The role of modelling in economic evaluation is well recognised in 
guideline development and at WHO, and was therefore excluded 
from discussions. At the workshop, we considered the results of 
a survey of experts (see Box 1) and a rapid literature review (see 
below). In this paper, which reflects the opinions of the authors but 
not necessarily that of all workshop participants, we first define 
models and modelling studies. We then address the three questions 
outlined above and conclude with some recommendations on the 
use of evidence from modelling studies in guidelines development.
What is a mathematical modelling study?
Using a common terminology across different disciplines, for 
example infectious disease modelling and modelling in chronic 
disease, will facilitate the assessment, evaluation and compari-
son of mathematical modelling studies. We define a mathematical 
model as a “mathematical framework representing variables and 
their interrelationships to describe observed phenomena or predict 
future events”4. Mathematical modelling studies are studies that 
address defined research questions using mathematical modelling, 
for example the potential of HIV testing with immediate antiretro-
viral therapy to reduce HIV transmission5, or the likely impact of 
different screening practices on the incidence of cervical cancer6. 
In contrast, statistical modelling is typically concerned with asso-
ciations between variables assessed in empirical studies, rather than 
Box 1. Web-based expert survey on the role of mathematical 
modelling in guideline development
The survey was conducted between March 17 and April 4, 
2016. It consisted of 10 questions: four on the characteristics 
of the respondents, three on the role of mathematical models 
in guideline development, two questions on quality criteria 
for mathematical models and one on the challenges in using 
mathematical modelling in guideline development (see  
Figure S1). Using snowball sampling, mathematical modellers, 
epidemiologists, guideline developers and other experts were 
invited to participate in the survey. A total of 151 individuals from 
28 countries and 87 different institutions responded. About half 
of respondents were modellers, and the other half users of the 
results from modelling studies. The majority of respondents (58%) 
had been part of a guideline development group in the past.
Ninety-five percent of respondents answered yes to the question 
“Should mathematical modelling inform guidance for public 
health interventions?” and 60% indicated that findings of 
mathematical modelling studies can sometimes provide the same 
level of evidence as those of empirical research studies. When 
asked to list situations in which mathematical modelling could be 
particularly useful for the development of guidelines, the absence 
of empirical data on the effectiveness, cost-effectiveness and 
impact of an intervention, and on the comparative effectiveness 
of different interventions was most frequently mentioned. We also 
asked about situations where mathematical modelling studies 
should not be used or have been inappropriately used in the 
development of guidelines. Respondents reported that modelling 
should not be used “to cover up” for the lack of evidence from 
empirical research, and due emphasis should be given to the 
uncertainty of model predictions. When asked about the five 
most important criteria for the quality of reporting of modelling 
studies, respondents mentioned that the model structure should 
be clearly described and justified, the important sources of 
uncertainty reported, and model validity addressed. Assumptions 
should be clearly stated, justified and discussed and the 
sources of parameter estimates described. Finally, respondents 
identified the interpretation of results from modelling studies, the 
evaluation of their quality and the communication of uncertainty 
as major challenges in using mathematical modelling in guideline 
development. These challenges would be best addressed by 
including at least one modelling expert in guideline development 
groups.
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an understanding of wider phenomena or systems. The results from 
statistical analyses of empirical data often inform mathematical 
models. Mathematical modelling studies also increasingly integrate 
statistical models into complex models to relate the model output 
to data.
Role of mathematical modelling studies in guideline 
development
Mathematical models typically address questions that cannot 
easily be answered with randomized controlled trials (RCTs) 
or observational studies. Table 1 lists specific situations and 
examples where the results of mathematical modelling are par-
ticularly relevant to guideline development, based on the survey, 
published examples and the Geneva workshop. Mathemati-
cal modelling can overcome some of the limitations of results 
obtained from the carefully controlled settings in which RCTs 
are typically conducted. First, the main trial results provide an 
average effect estimate that applies to a specific intervention and 
study population. Mathematical modelling studies can be used to 
extrapolate from the results of RCTs to different target groups and 
settings, to long term outcomes, and to bridge the gap between 
efficacy and (long-term) effectiveness7. Second, interventions to 
prevent and control infectious diseases have non-linear effects. 
RCTs that address short term effects at the individual level might 
not be suitable for estimating the longer term effects of introducing 
an intervention, say a vaccine, in a whole population if indirect herd 
effects influence the incidence of infection and hence the impact of 
the intervention8,9. Third, rapid guidance is often needed early in 
outbreaks or public health emergencies when relevant interventions 
for prevention or management might simply not have been evalu-
ated. The results of mathematical modelling studies can be used 
to draft emergency guidelines or to assess the epidemic potential 
of new outbreaks10.
The findings of mathematical modelling studies are only as good 
as the data and assumptions that inform them. Guideline recom-
mendations should therefore not be based on the outputs of models 
when uncertainty in the empirical data has not been appropriately 
quantified, when the model makes implausible assumptions or has 
not been validated adequately, or when the model predictions vary 
widely over a plausible range of parameter estimates.
Assessing the quality of a mathematical modelling 
study: Rapid review
We performed a rapid review of the methodological literature to 
identify criteria that are proposed to assess the “quality” of math-
ematical modelling studies (see Table S1 for the detailed search 
strategy). Specifically, we aimed to identify criteria proposed to 
assess the quality of single mathematical modelling studies, includ-
ing best practice standards or criteria for assessing risk of bias or 
reporting quality and criteria proposed to assess the quality of a 
body of evidence from mathematical modelling studies. We were 
also interested in identifying checklists or other instruments devel-
oped to assess the quality of mathematical modelling studies. 
Table 1. Situations in which mathematical modelling studies may be useful for guideline development.
Situation Examples of relevant mathematical modelling studies
The long-term effectiveness or cost-
effectiveness of an intervention is unclear.
Life time effect on decompensated cirrhosis of obeticholic acid as second-
line treatment in primary biliary cholangitis37. 
Outcomes and costs over 10 years of donepezil treatment in mild to 
moderately severe Alzheimer’s Disease38. 
Long-term clinical outcomes, costs and cost-effectiveness of interventions 
in diabetes mellitus (types 1 and 2)39.
The outcomes of an intervention in real world, 
routine care settings are unclear.
Outcomes of medical management of asymptomatic patients with carotid 
artery stenosis who were excluded from clinical trials40. 
Effects on blood pressure and cardiovascular risk of variations in patients’ 
adherence to prescribed antihypertensive drugs41.
The comparative (relative) effectiveness of 
different interventions overall or in subgroups 
of patients is unclear.
Comparative effectiveness of different statins and statin doses in patient 
groups with varying baseline cardiovascular risk42. 
Relative effect of different strategies of incorporating bevacizumab into 
platinum-based treatment on survival in ovarian cancer43. 
Relative real-world drug effectiveness of disease modifying anti-rheumatic 
drugs (DMARDs)44.
The overall effects of an intervention at the 
population level, including direct and indirect 
effects, are unknown.
Effects of different vaccination strategies with serogroup C meningococcal 
conjugate vaccines on meningococcal carriage and disease45. 
Public health impact of vaccinating boys and men with a quadrivalent HPV 
vaccine46. 
Impact of expanding access to antiretroviral therapy (“treatment as 
prevention”) on new HIV infections30.
The population burden of a disease or 
condition is unknown.
Estimate of the global burden of latent tuberculosis infection47. 
Burden of healthcare-associated infections on European population health48. 
Global variation in stroke burden and mortality49.
Source: WHO expert survey and consultation.
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We identified 20 relevant articles (see Figure 1 for a flow chart of 
the identification of eligible articles)9,11–28. Most gave recommen-
dations for good modelling practice and were compiled by a task 
force in a consensus process or based on a systematic or narrative 
review of the literature. The widely cited 2003 paper by Weinstein 
and colleagues organized 28 recommendations under the headings 
“structure”, “data”, and “validation”15. A questionnaire or check-
list was not included. A subsequent series of seven articles9,22–26,28 
by the joint International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and Society for Medical Decision 
Making (SMDM) task force elaborated upon these recommenda-
tions, providing detailed advice on conceptualizing the model, state 
transition models, discrete event simulations, dynamic transmis-
sion models, parameter estimation and uncertainty, and transpar-
ency and validation. The 79 recommendations are summarized in 
the first article of the series28.
We identified four articles16,18,21,27 that present comprehensive 
frameworks of good modelling practice, with detailed justifications 
of the items covered and attributes of good practice. They include 
signalling or helper questions to facilitate the critical appraisal of 
published modelling studies: the number of questions ranges from 
38 in Caro et al.16 to 66 questions in Bennett and Manuel21. The 
four frameworks cover similar territory, including items related to 
the problem concept, model structure, data sources and synthesis 
of the evidence, model uncertainty, consistency, transparency and 
validation (Table 2). Two of the frameworks include sponsorship 
and conflicts of interest16,21.
In a qualitative study Chilcot et al.11 performed in-depth interviews 
with 12 modellers from academic and commercial sectors, and 
model credibility emerged as the central concern of decision-makers 
using models. Respondents agreed that developing an understand-
ing of the clinical situation or disease process being investigated is 
paramount in ensuring model credibility, highlighting the impor-
tance of clinical input during the model development process11.
Model comparisons and modelling consortia
Published mathematical models addressing the same issue may 
reach contrasting conclusions. In this situation, careful comparison 
of the models may lead to a deeper understanding of the factors 
that drive outputs and conclusions. Ideally, the different model-
ling groups come together to explore the importance of differences 
in the type and structure of their models, and of the data used to 
parameterize them29–31. For example, several groups of modellers 
have investigated the impact of expanding access to antiretrovi-
ral therapy (ART) on new HIV infections. The HIV Modelling 
Consortium compared the predictions of several mathematical 
models simulating the same ART intervention programs to determine 
the extent to which models agree on the epidemiological impact of 
expanded ART30. The consortium concluded that although models 
vary substantially in structure, complexity, and parameter choices, 
all suggested that ART, at high levels of access and with high 
adherence, has the potential to substantially reduce new HIV infec-
tions in the population30. There was broad agreement regarding the 
short-term epidemiologic impact of ART scale-up, but more 
variation in longer-term projections and in the efficiency with which 
Figure 1. Rapid review of literature on good practice in mathematical modelling: flow of identification of eligible studies.
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Table 2. Items covered by four published frameworks developed to assess good modelling practice.
Philips 200618 Bennett 201221 Caro 201416 Peñaloza Ramos 201527
Structure  
Decision problem/objective 
Scope/perspective 
Rationale for structure 
Structural assumptions 
Strategies/comparators 
Model type 
Time horizon 
Disease states/pathways 
Cycle length 
Data  
Data identification 
Pre-model data analysis 
Baseline data 
Treatment effects 
Utilities 
Data incorporation 
Assessment of uncertainty 
Methodological 
Structural 
Heterogeneity 
Parameter 
Consistency  
Internal consistency 
External consistency
Structure  
Decision problem/objective 
Scope/perspective 
Rationale for structure 
Structural assumptions 
Strategies/comparators 
Model type 
Time horizon 
Disease states/pathways 
Cycle length 
Parsimony 
Data  
Data identification 
Data modelling 
Baseline data 
Treatment effects 
Risk factors 
Data incorporation 
Assessment of uncertainty 
Methodological 
Structural 
Heterogeneity 
Parameter 
Consistency  
Internal consistency 
External consistency 
Validity  
Output plausibility 
Predictive validity 
Computer implementation  
Transparency  
Sponsorship 
RELEVANCE  
Population 
Interventions 
Outcomes 
Context 
CREDIBILITY  
Validation  
External validation 
Internal verification 
Face validity 
Design  
Problem concept 
Model concept and structure 
Data  
Process of obtaining and  
    values of inputs 
Analysis  
Adequacy 
Uncertainly 
Reporting  
Adequacy 
Interpretation  
Balance 
Conflict of interest  
Potential conflicts and steps 
    taken to address them
Problem concept  
Decision problem 
Analytical perspective 
Target population 
Health outcomes 
Comparators 
Time horizon 
Model concept  
Choice of model type 
Model structure 
Synthesis of evidence  
Data sources 
Utilities 
Cycle length and half-cycle correction 
Resources/costs 
Patient heterogeneity 
Parameter precision 
Model uncertainty  
Analyses of uncertainty related to the 
     decision problem 
Parameter estimation 
Structural uncertainty 
Other analyses of uncertainty 
Model transparency and validation  
Transparency 
Validation 
Face validity 
Internal validity 
Cross-validation 
External validity 
Predictive validity
treatment can reduce new infections. The impact of ART on HIV 
incidence long-term is expected to be lower if models: (i) allow for 
heterogeneity in sexual risk behaviour; (ii) are age-structured; (iii) 
estimate a low proportion of HIV transmission from individuals not 
on ART with advanced disease (at low CD4 counts); (iv) are com-
pared to what would be expected in the presence of HIV counselling 
and testing (compared to no counselling and testing); (v) assume 
relatively high infectiousness on ART; and (vi) consider drug 
resistance30,32,33.
Assessing mathematical modelling studies using the 
GRADE approach
GRADE was conceived with the intention of creating a uniform 
system to assess a body of evidence to support guideline develop-
ment in response to a confusing array of different systems in use 
at that time34. It has since been adopted by over 90 organisations, 
including WHO. GRADE addresses clinical management ques-
tions, including the impact of therapies and diagnostic strate-
gies, diagnostic accuracy questions (i.e., the accuracy of a single 
diagnostic or screening test), the (cost-) effectiveness and safety of 
public health interventions, and questions about prognosis.
The GRADE approach encompasses two main considerations: 
the degree of certainty in the evidence used to support a decision 
and the strength of the recommendation. The degree of certainty, 
i.e., the confidence in or quality of a body of evidence, is rated 
as “high”, “moderate”, “low”, or “very low” based on an assess-
ment of five dimensions: study limitations (risk of bias), impreci-
sion, inconsistency, indirectness, and publication bias. The initial 
assessment is based on the study design: RCTs start as high 
certainty and observational studies as low certainty. Based on the 
assessments of the five dimensions, RCTs may be down-rated and 
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observational studies up- or down-rated. Judgment is required 
when assessing the certainty of the evidence, taking into account 
the number of studies of higher and lower quality and the relative 
importance of the different dimensions in a given context. The sec-
ond consideration is the strength of the recommendation, which 
can be “strong” or “conditional”, for or against an intervention or 
test, based on the balance of benefits and harms, certainty of the 
evidence, the relative values of persons affected by the interven-
tion, resource considerations, acceptability and feasibility, among 
others35. 
We believe that evidence from mathematical modelling studies 
could be assessed within the GRADE framework and included in 
the guideline development process. Specifically, guideline groups 
might include mathematical modelling studies as an additional 
study category, in addition to the categories of RCTs and obser-
vational studies currently defined in GRADE. The dimensions of 
indirectness, inconsistency, imprecision and publication bias are 
applicable to mathematical modelling studies, but criteria may 
need to be adapted. The concept of bias relates to results or infer-
ences from empirical studies36. “Lack of credibility” may there-
fore be a more appropriate term for modelling studies than “risk 
of bias”. The assessment of the credibility of a model is informed 
by a comprehensive quality framework and should cover the con-
ceptualization of the problem, model structure, input data, different 
dimensions of uncertainty, as well as transparency and validation 
(Table 2). The framework should be tailored to each set of model-
ling studies by adding or omitting questions and developing review-
specific guidance on how to assess each criterion. The certainty of 
the body of evidence from modelling studies can then be classified 
as high, moderate, low, or very low. In the evidence-to-decision 
framework a distinction should be made between observed 
outcomes from empirical studies and modelled outcomes from 
modelling studies (see an example). 
Conclusions and recommendations
Based on the discussions and presentations at the workshop in 
Geneva, the survey and rapid systematic review, we believe a 
number of conclusions can be formulated.
When is it appropriate to consider modelling studies as 
part of the evidence that supports a guideline?
1.    The use of modelling studies should routinely be considered in 
the process of developing WHO guidelines. Findings of math-
ematical modelling studies can provide important evidence that 
may be highly relevant. Evidence from modelling studies 
should be considered specifically in the absence of empirical 
data directly addressing the question of interest, when model-
ling based on appropriate indirect evidence may be indicated. 
Examples for such situations include the evaluation of long-term 
effectiveness, and the impact of one or several interventions 
(comparative effectiveness), for example in the context 
of public health programmes where RCTs are rarely 
available.
2.    Modelling may be more acceptable and more influential in 
situations where immediate action is called for, but little direct 
empirical evidence is available, and may arguably be more 
acceptable in public health than in clinical decision making. In 
these situations (for example, the HIV, Ebola, or Zika epidemics) 
funding is also likely to become available to support dedicated 
modelling studies.
3.    The use of evidence from mathematical models should be 
carefully considered and there should be a systematic and trans-
parent approach to identifying existing models that may be 
relevant, and to commissioning new models.
How should the credibility of mathematical modelling 
studies be assessed?
4.    No single “one-size-fits-all” approach is appropriate to assess 
the quality of modelling studies. Existing frameworks and 
checklists may be adapted to a set of modelling studies by add-
ing or omitting questions. In some situations, the approach will 
need to be developed de novo.
5.    Additional expertise will typically be required in the systematic 
review groups or guideline development groups to appropri-
ately assess the credibility of modelling studies and interpret 
their results.
6.    The credibility of the models should not be evaluated only by 
modellers, and not only by modellers involved in the develop-
ment of these models.
How can the GRADE approach be adapted to assess a 
body of evidence that includes the results of modelling and 
to formulate recommendations?
7.      The inclusion of evidence from modelling studies into the 
GRADE process is possible and desirable, with relatively few 
adaptations. GRADE is simply rating the certainty of evidence to 
support a decision and any type of evidence can in principle 
be included.
8.      The certainty of the evidence for modelling studies should 
be assessed and presented separately in summaries of the 
evidence (GRADE evidence profiles), and classified as high, 
moderate, low, or very low certainty.
9.      The GRADE dimensions of certainty (imprecision, indirectness, 
inconsistency and publication bias) and the criteria defined 
for their assessment are also relevant to modelling studies.
10.    For modelling studies, the concept of the ‘credibility’ of 
the model, which takes the structure of the model, input 
data, dimensions of uncertainty, as well as transparency and 
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validation into account, is more appropriate than ‘study limita-
tions’ or ‘risk of bias’.
11.    When summarizing the evidence, a distinction should be made 
between observed and modelled outcomes.
We look forward to discussing these recommendations with experts 
and stakeholders and to developing exact procedures and criteria 
for the assessment of modelling studies and their inclusion in the 
GRADE process.
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In this opinion article, the authors discuss when and how to incorporate the results of modelling studies
into WHO guidelines, by addressing three questions: (1) When is it appropriate to consider modelling
studies as part of the evidence that supports a guideline? (2) How should the quality and risk of bias in
mathematical modelling studies be assessed? (3) How can the GRADE approach be adapted to assess
the certainty of a body of evidence that includes the results of modelling and to formulate
recommendations? Based on findings from a web-based expert survey, a rapid literature review to
identify criteria for assessing the “quality” of mathematical modelling studies, and on discussions and
presentations at a workshop on the topic that was held April 2016 in Geneva, the authors conclude that
modelling studies should indeed routinely be considered in the process of developing WHO guidelines,
particularly in the evaluation of public health programmes, long-term effectiveness or comparative
effectiveness. As for other types of evidence taken into consideration, there should be a systematic and
transparent approach to identifying existing models that may be relevant and the quality and credibility of
models should be systematically assessed. Relatively few adaptations are needed in the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) approach to rate the certainty of
a body of evidence and to produce information that is used by guideline panels to formulate
recommendations, based on the balance of benefits and harms and other considerations.
MINOR COMMENTS:
Recommendation 4 is “No single ‘one-size-fits-all’ approach is appropriate to assess the quality of
modelling studies. Existing frameworks and checklists may be adapted to a set of modelling
studies by adding or omitting questions. In some situations, the approach will need to be
developed  .” I’d prefer to turn it around: based on existing frameworks and checklists,de novo
generic criteria can be developed to assess the quality of modelling studies, although – depending
on the situation –questions may have to be added or omitted. I am not convinced that in some
situations a completely new approach is needed, and this would also not be advisable. The
authors should either delete the last statement, or explain under which circumstances such a new
approach is needed, ideally illustrated with an example.
 
Recommendation 8 is “The certainty of the evidence for modelling studies should be assessed and
presented separately in summaries of the evidence (GRADE evidence profiles), and classified as
high, moderate, low, or very low certainty.” In the text, the authors state that RCTs start as high
certainty and observational studies as low certainty, although this certainty score may be up- or
down-rated based on detailed assessment of five dimensions. Is it possible to give an indication of
where modelling studies would start, with a justification? If not, can the authors describe factors to
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down-rated based on detailed assessment of five dimensions. Is it possible to give an indication of
where modelling studies would start, with a justification? If not, can the authors describe factors to
be considered when determining the start class? 
 
The questionnaire of the online survey on the use of mathematical modelling in guidelines for
public health decision making is included as Figure S1, which combines a series of screen shots.
The quality of this figure is poor and I recommend to include the questionnaire as a text document.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Are arguments sufficiently supported by evidence from the published literature?
Yes
Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes
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